Group 1: CaoCao Inc. (曹操出行) - CaoCao Inc. officially listed on the Hong Kong Stock Exchange on June 25, 2025, with the stock code "2643" [3] - Established in 2015, CaoCao has become one of the largest ride-hailing platforms in China, covering 136 cities as of December 31, 2024, with 85 new cities added in 2024 [3] - The total Gross Transaction Value (GTV) for 2023 and 2024 was 12.2 billion yuan and 17 billion yuan, representing growth rates of 37.5% and 38.8% respectively [3] - In Q1 2024, CaoCao's GTV reached 4.8 billion yuan, a 54.9% increase year-on-year, with order volume growing by 51.8% [3][5] - The company operates a fleet of over 34,000 customized vehicles, making it the largest fleet in China according to Frost & Sullivan [4] - CaoCao launched an autonomous driving platform in February 2024 and plans to introduce L4-level Robotaxi models by the end of 2026 [4] Group 2: SAINT BELLA Inc. (圣贝拉) - SAINT BELLA Inc. listed on the Hong Kong Stock Exchange on June 26, 2025, with the stock code "2508" [7] - The company operates 96 high-end postpartum care centers under various brands, with significant growth in self-operated and managed centers from 2022 to 2024 [7] - SAINT BELLA is recognized as the largest postpartum care and recovery group in China and Asia, with a market share of approximately 1.2% in 2024 [7] Group 3: BoKang Vision Cloud (拨康视云) - BoKang Vision Cloud plans to list on the Hong Kong Stock Exchange on July 3, 2025, with an IPO market value of approximately 8.473 billion HKD [10] - The company focuses on developing ophthalmic biotechnologies, with two core products in clinical trials for treating pterygium and myopia [11] Group 4: Stand Robot (斯坦德机器人) - Stand Robot submitted its IPO application on June 23, 2025, aiming to become the first industrial embodiment intelligent robot stock [13] - The company is recognized as the fifth largest industrial mobile robot solution provider globally, with significant growth in overseas revenue [14] - From 2022 to 2024, Stand Robot's revenue grew from 96 million yuan to 251 million yuan, with a compound annual growth rate of 61.3% [14] Group 5: Megatech (镁伽科技) - Megatech submitted its IPO application on June 25, 2025, and is the largest domestic autonomous intelligent body supplier in China [17] - The company reported a revenue growth from 455 million yuan in 2022 to 930 million yuan in 2024, with a compound annual growth rate of 43.0% [18] Group 6: Yikong Intelligent Driving (易控智驾) - Yikong Intelligent Driving plans to list on the Hong Kong Stock Exchange on June 25, 2025, and is the largest provider of L4-level autonomous driving solutions in the mining sector [21] - The company achieved a revenue increase from 60 million yuan in 2022 to 986 million yuan in 2024, with a compound annual growth rate of 305.8% [22] Group 7: Weimai (微脉) - Weimai submitted its IPO application on June 27, 2025, focusing on AI-driven full-process management services in healthcare [24] - The company reported revenue growth from 512 million yuan in 2022 to 653 million yuan in 2024, with a gross margin increase from 17.2% to 19.9% [25] Group 8: Cloud Yinggu (云英谷) - Cloud Yinggu submitted its IPO application on June 26, 2025, and is the largest AMOLED display driver chip manufacturer in mainland China [28] - The company reported a revenue increase from 551 million yuan in 2022 to 891 million yuan in 2024 [30] Group 9: Chengtai Technology (承泰科技) - Chengtai Technology submitted its IPO application on June 23, 2025, and is the largest supplier of vehicle-mounted millimeter-wave radar in China [33] - The company achieved a revenue increase from 58 million yuan in 2022 to 348 million yuan in 2024, with a compound annual growth rate of 145.7% [33] Group 10: Siwei Zhili (四维智联) - Siwei Zhili submitted its IPO application on June 27, 2025, and is a leading provider of intelligent cockpit solutions in China [36] - The company reported revenue of 539 million yuan in 2022, with a slight decline in subsequent years [36] Group 11: Haima Cloud (海马云) - Haima Cloud submitted its IPO application on June 27, 2025, and is the largest GPUaaS provider for real-time cloud rendering in China [40] - The company reported revenue growth from 290 million yuan in 2022 to 520 million yuan in 2024, with a compound annual growth rate of 33.8% [41] Group 12: Jingze Biopharma (景泽生物) - Jingze Biopharma submitted its IPO application on June 27, 2025, focusing on reproductive and ophthalmic pharmaceuticals [44] - The company has raised 927 million yuan in funding and has a pre-IPO valuation of 3.09 billion yuan [45] Group 13: Immvira Bioscience (亦诺微医药) - Immvira Bioscience submitted its IPO application on June 25, 2025, focusing on oncolytic immunotherapy and engineered exosome therapy [47] - The company has a pre-IPO valuation of 485 million USD [48]

Core Viewpoint - Haima Cloud is positioned as a leading provider of GPUaaS in China, focusing on real-time cloud rendering services for various industries, including gaming and digital entertainment, with a strategic plan for IPO in 2025 [2][3]. Group 1: Company Overview - Established in 2013, Haima Cloud is the first company in China to design and develop its own servers for real-time cloud rendering [2]. - Since 2019, the company has strategically deployed GPUaaS on a large scale, becoming the largest provider of real-time cloud rendering services in China [2]. - As of December 31, 2024, Haima Cloud serves nine out of the top ten market participants in China's cloud gaming industry and has partnerships with major players like China Mobile and leading game developers [2]. Group 2: Market Position - According to Zhaosheng Consulting, Haima Cloud ranks first among real-time cloud rendering service providers in China's cloud gaming sector, holding a market share of 17.9% based on 2024 revenue [3]. Group 3: Infrastructure and Expansion - Haima Cloud operates over 10,000 GPU servers and 63 high-performance GPU computing nodes globally, making it one of the largest and most widely distributed GPU computing infrastructures for real-time cloud rendering in China [4]. - The company has established computing nodes in countries such as Singapore and Vietnam, with ongoing deployments in the UK, France, Germany, Japan, South Korea, Australia, Poland, and Canada [4]. Group 4: Financial Performance - Revenue figures for Haima Cloud from 2022 to 2024 are as follows: CNY 290 million, CNY 337 million, and CNY 520 million, reflecting a compound annual growth rate (CAGR) of 33.8% [4]. - Gross profit for the same period was CNY 62 million, CNY 89 million, and CNY 129 million, with a CAGR of 44.9% [4]. - The gross margin percentages were 21.2%, 26.6%, and 24.9% for the years 2022, 2023, and 2024, respectively [4]. Group 5: IPO Fund Utilization - The net proceeds from the IPO will primarily be used for continuous infrastructure investment, funding R&D related to core platform software, developing and promoting emerging products, and supporting ongoing development of gaming AI capabilities [5].

Core Viewpoint - Siwei Zhihui (Nanjing) Technology Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, aiming to enhance its market position in the intelligent cockpit solutions sector [2][3]. Company Overview - Founded in 2015, Siwei Zhihui is a supplier of intelligent cockpit solutions, controlled by Siwei Tuxin Group. As of 2024, it ranks tenth among domestic primary intelligent cockpit solution providers with a market share of 0.1%, and third among software-driven primary suppliers globally [3]. - The company has delivered over 15.9 million intelligent cockpit software solutions and more than 1.55 million integrated hardware-software solutions to approximately 20% of China's vehicle manufacturers [3]. Financial Performance - Revenue figures for Siwei Zhihui from 2022 to 2024 are as follows: 539 million RMB, 477 million RMB, and 479 million RMB. The gross margins during the same period were 30.2%, 29.4%, and 29.2%, respectively. Adjusted net losses were 14 million RMB, 60 million RMB, and 133 million RMB [3]. Investment and Valuation - Major investors in Siwei Zhihui include Didi, MediaTek, Yihua Fund, Tencent, and others. Didi holds a 16.46% stake, making it the largest external investor [4]. - Following the last round of financing before the IPO in August 2024, Siwei Zhihui's valuation reached 4.07 billion RMB. The funds raised from the IPO will primarily be used for capacity building, technology research and development, and general corporate purposes [5].

Core Viewpoint - Jingze Biopharmaceuticals is preparing for an IPO on the Hong Kong Stock Exchange, focusing on reproductive and ophthalmic drugs, and is one of the leading companies in China with the most clinical-stage macromolecule drugs in these fields [1][3]. Summary by Sections - Jingze Biopharmaceuticals submitted its prospectus for an IPO on June 27, 2025, with CICC and Guoyuan International as joint sponsors. The company, established in 2014, specializes in reproductive and ophthalmic drugs [1]. - As of June 20, 2025, Jingze's core product in reproductive treatment, JZB30 (rhFSH lyophilized powder injection), has been approved for commercialization, while JZB33 (rhFSH aqueous injection) has submitted an NDA. In the ophthalmic field, JZB05 (anti-VEGF intravitreal injection) is undergoing Phase III clinical trials at over 40 centers in mainland China [2][3]. - JZB30 is Jingze's first commercialized product in reproductive treatment, serving as a follicle-stimulating hormone for ovulation induction. JZB05 is expected to be the first commercial product in the ophthalmic field, targeting diseases like wAMD and DME. JZB30 is a biosimilar to the leading imported product, while JZB05 is a biosimilar to the top-selling anti-VEGF drug, with the latter projected to achieve $9.5 billion in annual sales by 2024 [4]. - Since its inception, Jingze Biopharmaceuticals has completed financing totaling 927 million yuan, with a valuation of 3.09 billion yuan following its last round of financing before the IPO. The net proceeds from the IPO will primarily be used to advance core product development, clinical trials for key products, and general corporate purposes [4].

Core Viewpoint - Rongrui Technology focuses on green manufacturing in fields such as industrial enzyme preparations, health foods, pharmaceutical chemicals, and functional new materials, leveraging synthetic biology and artificial intelligence to develop disruptive technologies for green bio-manufacturing [1][2]. Group 1: Company Overview - Rongrui Technology was established in 2022 and has successfully developed dozens of products, including key industrial enzyme varieties such as lipase and amide enzymes, as well as high-value fine chemicals and health products [1]. - The company has formed multiple collaborations with leading enterprises in its niche sectors [1]. Group 2: Recent Financing - Rongrui Technology recently completed nearly 100 million yuan in Pre-A round financing, led by PwC Capital and Dinghui VGC, with Kai Cheng Capital serving as the exclusive financial advisor [1]. - The funds raised will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization processes [1]. Group 3: Management and Investor Insights - The CEO of Rongrui Technology expressed gratitude for the support from investors and emphasized the company's commitment to enhancing technology, production facilities, and commercial channels to ensure sustained growth [2]. - Investors from PwC Capital and Dinghui VGC highlighted the team's extensive industrial experience and solid R&D foundation, expressing confidence in the company's growth prospects and its ability to create social value through its strong technology platform [3].

Core Viewpoint - The article emphasizes that Huaxing Capital is strategically transitioning into the WEB 3.0 and digital asset sectors, aiming to become a core player in global WEB 3.0 investments while leveraging its existing strengths in traditional finance [1][5]. Personnel Changes - Huaxing Capital appointed Frank Fu Kan and Chen Jiali as independent non-executive directors, both bringing extensive industry experience, particularly in blockchain technology and digital currencies [2]. Business Strategy - The company has approved a budget of $100 million to develop its WEB 3.0 business and invest in digital currency assets over the next two years, focusing on stablecoins, RWA (real-world assets), and the entire digital asset ecosystem [1][5]. - The board's strategic move is part of Huaxing's "2.0 era" initiative, which aims to solidify its existing business while expanding into new technology-driven sectors [3][5]. Performance and Achievements - Huaxing Capital has shown a strong recovery in its overall business, particularly in artificial intelligence and mergers and acquisitions, with significant IPO successes, including the notable performance of Circle Internet Group [3][4]. - The company has a history of successful investments in the blockchain sector, including leading roles in the IPOs of various tech firms [4]. Future Outlook - The strategic focus on artificial intelligence, mergers and acquisitions, and blockchain technology positions Huaxing Capital as a bridge between Web 2.0 and Web 3.0, enhancing its industry leadership and shareholder value [5].

Core Viewpoint - The article discusses the upcoming IPO of Weimai, a leading AI-driven full-cycle management service provider in China, highlighting its growth potential and market position in the healthcare sector [2][3][5]. Group 1: Company Overview - Weimai, established in 2013, focuses on utilizing AI technology to enhance healthcare services by connecting hospitals, doctors, and patients, thereby restructuring the value chain of medical services [3]. - As of June 20, 2025, Weimai has signed contracts with 157 hospitals and has provided full-cycle management services to approximately 500,000 patients across over 80 disease categories [12][13]. Group 2: Financial Performance - Weimai's revenue is projected to grow from RMB 511.9 million in 2022 to RMB 652.7 million in 2024, representing a 27.5% increase, driven by stable growth in full-cycle management service income [7]. - The gross margin is expected to improve from 17.2% in 2022 to 19.9% in 2024, indicating enhanced operational efficiency [7]. - Adjusted net losses are forecasted to decrease significantly from RMB 233.3 million in 2022 to RMB 30.2 million in 2024, with the adjusted net loss margin narrowing from 45.6% to 4.6% [8]. Group 3: Market Potential - The full-cycle management market in China has grown from RMB 16.3 billion in 2020 to an estimated RMB 61.4 billion in 2024, with a projected compound annual growth rate (CAGR) of 34.6% reaching RMB 365.4 billion by 2030 [15]. - The shift in China's healthcare model towards comprehensive management solutions is driven by government initiatives, creating strategic opportunities for companies like Weimai to enhance hospital efficiency and patient care [14][16]. Group 4: Investment and Future Plans - Weimai has attracted investments from notable firms and government funds, with IPO proceeds aimed at enhancing AI capabilities, expanding service offerings, and strategic acquisitions in specialized medical sectors [17].

Core Viewpoint - Yunyinggu Technology Co., Ltd. is set to go public on the Hong Kong Stock Exchange, marking a significant step after previous attempts to list in A-shares and a failed acquisition by Huida Technology [2][5]. Company Overview - Established in 2012, Yunyinggu specializes in AMOLED display driver chip design, providing solutions for consumer electronics brands [2]. - As of 2024, Yunyinggu is the largest AMOLED display driver chip manufacturer in mainland China and the fifth largest globally, according to Frost & Sullivan [2][3]. Technology and Market Position - The company has developed a comprehensive self-research display driver technology, covering chip design, compensation algorithm development, and pixel compensation circuit layout [3]. - By the end of 2024, Yunyinggu's AMOLED display driver chips will have been shipped to multiple leading smartphone brands, accounting for over 25% of the global market share [3]. Sales Performance - From 2022 to 2024, Yunyinggu's sales volume of AMOLED display driver chips increased from approximately 14.1 million to 51.4 million units, with a compound annual growth rate (CAGR) of 71.3% [4]. - The company's market share in the global smartphone AMOLED display driver chip supply rose from 1.2% in 2022 to 4.0% in 2024 [3]. Financial Performance - Yunyinggu's revenue for the years 2022, 2023, and 2024 was approximately 551 million, 720 million, and 891 million yuan, respectively [5]. - The gross profit margins for the same period were 31.9%, 0.4%, and 2.5%, with adjusted net profit margins of 0.1%, -30.2%, and 25.1% [5]. IPO Fund Utilization - The funds raised from the IPO will primarily support the research and optimization of AMOLED TDDI chips, development of Micro-OLED and Micro-LED display driver backplanes, strategic investments or acquisitions, and general working capital [5].

Core Viewpoint - MVR-T3011 is a potential best-in-class oncolytic immunotherapy for bladder cancer, expected to change the global treatment landscape for this disease [2]. Company Overview - Immvira Bioscience is the only biotechnology company globally with mature CMC and production capabilities, focusing on discovering, developing, producing, and commercializing novel oncolytic immunotherapies and engineered exosome therapies [3]. - The company has submitted its IPO application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [3]. Product Details - MVR-T3011 is a novel oncolytic immunotherapy based on HSV-1, combining potent tumor lysis with the expression of anti-PD-(L)1 antibodies and IL-12, targeting a wide range of bladder cancers and other solid tumor types [4]. - The replication capacity of MVR-T3011 has been enhanced by three logarithmic decades, supporting multiple administration routes, including intratumoral, intravesical, and intravenous delivery, significantly expanding its clinical applicability [4]. - In clinical studies, MVR-T3011 demonstrated excellent efficacy and safety, achieving 85.9%, 77.3%, 77.3%, and 66.3% Kaplan-Meier estimated recurrence-free survival rates at 3, 6, 9, and 12 months, respectively, outperforming Ferring's ADSTILADRIN®, the first and only FDA-approved intravesical gene therapy [4]. Collaboration and Financials - In 2020, Immvira entered into a licensing agreement with Shanghai Pharmaceuticals for MVR-T3011, granting exclusive clinical development and commercialization rights in Greater China [5]. - The company received an initial payment of 20 million yuan and a patent licensing fee of 30 million yuan, with potential milestone payments up to 1.1 billion yuan and a sales revenue share [5]. Innovation Platform - The OVPENS platform is the core engine for the company's innovative product development, integrating oncolytic immunotherapy and engineered exosome development, covering the entire process from target validation to IND application and GMP-compliant production [5]. - OVPENS accelerates vector construction, effective payload optimization, and preclinical evaluation, enabling rapid iteration and efficient advancement across therapies and disease scenarios [5]. Aesthetic Products - The company is developing aesthetic products such as MVR-EX103 for skin-related issues, MVR-EX104 to stimulate comprehensive hair growth, and MVR-EX105 to promote browning of white fat while stimulating muscle growth [7]. - These external exosome products will enter overseas retail markets upon obtaining INCI naming [7]. Valuation - The post-investment valuation of the company in the C+ round is reported to be 485 million USD [8].

Core Viewpoint - SAINT BELLA Inc. has successfully listed on the Hong Kong Stock Exchange, becoming the "first stock of global family quality care" with significant investor interest and a strong market debut [2][4]. Company Overview - Founded in 2017, SAINT BELLA has rapidly grown to become the largest postpartum care group in China and Asia, operating in 30 cities globally [4][5]. - The company operates 96 high-end postpartum care centers under various brands, with a mix of self-operated and managed centers [5][6]. Business Expansion - SAINT BELLA has expanded its services beyond postpartum care to include family care services and functional health foods for women, enhancing customer lifecycle value [5][6]. - The company has established a significant presence in international markets, including Hong Kong, Singapore, and the United States [5][6]. Financial Performance - Revenue growth from 2022 to 2024 shows an increase from 472 million to 799 million yuan, with a return to profitability in 2023 [7]. - The adjusted net profit for 2023 was 20.77 million yuan, increasing to 42.25 million yuan in 2024 [7]. Market Position - SAINT BELLA holds a market share of approximately 1.2% in the Chinese postpartum care sector, making it the largest and fastest-growing group in this industry [6][7]. - The company has a strong customer retention rate, with 84% of postpartum care clients also utilizing other services [6]. Investment and Support - The company has attracted investments from notable firms, including Tencent and Gao Rong Capital, which has been involved since 2018 [9][10]. - Gao Rong Capital's managing director highlighted the company's rapid growth and adaptability in a competitive market [12][13].